Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5104-5111

  Ogura, Kenichiro ^a   Ohnuma, Tomokazu ^a   Minamide, Yoshiyuki ^b   Mizuno, Atsuhiro ^b   Nishiyama, Takahito ^a   Nagashima, Satoru ^c   Kanamaru, Mitsutaka ^c   Hiratsuka, Akira ^a   Watabe, Tadashi ^a   Uematsu, Toshihiko ^c,d  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b Development and Medical Affairs Division   (Japan)

^c Shitoro Clinic   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; ALLELE; ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; ETHNOLOGY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; MUTATIONAL ANALYSIS; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; GENETIC SCREENING; HUMANS; JAPAN; MALE; MIDDLE AGED;

EID: 22344439751     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0217     Document Type: Article

References (50)

1. Lu Z-H, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992;267:17102-9.
2. Milano G, Etienne MC. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Res 1994;14:2295-7.
3. Grem JL. Fluoropyrimidines. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy, 2nd ed. Philadelphia: Lippincott-Raven; 1996. p. 149-97.
4. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-6.
5. Takimoto CH, Lu Z-H, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996;2:477-81.
6. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53:5433-8.
7. Milano G, Etienne MC, Pierrefite V, Barberi-Heyyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999;79:627-30.
8. Daher GC, Naguib FN, el Kouni MH, Zhang RW, Soong SJ, Diasio RB. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. Biochem Pharmacol 1991;41:1887-93.
9. Okuda H, Nishiyama T, Ogura K, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracilprodrugs. Drug Metab Dispos 1997; 25:270-3.
10. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998;287:791-9.
11. Ogura K, Nishiyama T, Takubo H, et al. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett 1998;122:107-13.
12. Nishiyama T, Ogura K, Okuda H, Suda K, Kato A, Watabe T. Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl) uracil in the presence of NADPH. Mol Pharmacol 2000;57:899-905.
13. Kanamitsu S, Ito K, Okuda H, et al. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (F)-5-(2-bromovinyl) uracil. Drug Metab Dispos 2000;28:467-74.
14. Fleming RA, Milano GA, Gaspard MH, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993;29A:740-4.
15. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53:5433-8.
16. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
17. Lu Z, Zhang R, Diasio MD. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995;58:512-22.
18. Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997;3:395-9.
19. Sohn DR, Cho MS, Chung PJ. Dihydropyrimidine dehydrogenase activity in a Korean population. Ther Drug Monit 1999;21:152-4.
20. Morsman JM, Sludden J, Ameyaw MM, et al. Evaluation of dihydropyrimidine dehydrogenase activity in south-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol 2000;50:269-72.
21. Hamdy SI, Hiratsuka M, Narahara K, et al. Allele genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002;53:596-603.
22. Celik I, Kars A, Guc D, Tukuzman G, Ruacan S. Dihydropyrimidine dehydrogenase deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 2002;20:333-9.
23. Kouwaki M, Hamajima N, Sumi S, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998;4:2999-3004.
24. Sumi S, Kidouchi K, Ohba S, Wada Y. Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 672:233-9.
25. Yokota H, Fernandez-Salguero P, Furuya H, et al. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 1994;269:23192-6.
26. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
28. Towbin H, Staehelin T, Gordon J, et al. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
29. Fleming GF, Vokes EE, Buse JB, et al. Peripheral blood mononuclearcell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. Cancer Chemother Pharmacol 1996;37: 569-73.
30. Sumi S, Kidouchi K, Hayashi K, Imaeda M, Asai M, Wada Y. Urinary screening for pyrimidine metabolism disorders: reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio. Adv Exp Med Biol 1998; 431:191-5.
31. Meinsma R, Fernandez-Salguero van Kuilenburg ABP, van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995;14:1-6.
32. McLeod HL, Collie-Duguid ESR, Vreken P, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998;8:455-9.
33. Collie-Duguid ESR, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000;10:217-23.
34. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002;8:768-74.
35. Marnig JG, van Kuilenburg ABP, Haasjes J, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002;86:1028-33.
36. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003;8:132-8.
37. van Kuilenburg ABP, Baars JW, Meinsma R, van Gennip AH. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol 2003;14:341-2.
38. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004;4:181-9.
39. Zhu AX, Puchalski TA, Stanton VP Jr, et al. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer 2004;4:225-34.
40. Yamaguchi K, Arai Y, Kanda Y, Kiwamu A. Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001;92:337-42.
41. Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998;51:391-400.
42. Kimura M, Sakata SF, Matoba Y, et al. Cloning of rat dihydropyrimidine dehydrogenase and correlation of its mRNA increase in the rat liver with age. J Nutr Sci Vitaminol 1998;44:537-46.
43. Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics 2002;12:133-44.
44. Albin N, Johnson MR, Diasio RB. cDNA cloning of bovine liver dihydropyrimidine dehydrogenase. DNA Seq 1996;6:243-50.
45. Dobritzsch D, Schneider G, Schnackerz KD, Lidqvist Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J 2001;20: 650-60.
46. Cardoso RM, Thayer MM, DiDonato M, Lo TP, Bruns CK, Getzoff ED. Insights into Lou Gehrig's disease from the structure and instability of the A4V mutant of human Cu, Zn superoxide dismutase. J Mol Biol 2002;324:247-56.
47. Nakamura K, Watanabe M, Takanaka K, Sasaki Y, Ikeda T. cDNA cloning of mutant catalase in acatalasemic beagle dog: single nucleotide substitution leading to thermal-instability and enhanced proteolysis of mutant enzyme. Int J Biochem Cell Biol 2000; 32:1183-93.
48. Collie-Duguid ESR, Johnston SJ, Powrie RH, et al. Cloning and initial characterization of the human DPYD gene promoter. Biochem Biophys Res Commun 2000;271:28-35.
49. Milano G, Etienne M-C. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 1994;4:301-6.
50. Chazal M, Etienne MC, Renée N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 1996; 2:507-10.